chemic
synthes
short
interf
rna
sirna
predetermin
sequenc
usher
new
era
applic
rna
interfer
rnai
viral
gene
paid
particular
attent
respiratori
virus
wreak
heavi
morbid
mortal
worldwid
clinic
signific
one
includ
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
influenza
viru
infect
virus
clinic
restrict
respiratori
tissu
mainli
lung
logic
rout
applic
sirna
also
ie
via
nasal
rout
follow
initi
success
intranas
sirna
rsv
secondgener
sirna
made
viral
polymeras
larg
subunit
l
chemic
modifi
screen
improv
stabil
activ
pharmacokinet
omethyl
fluoro
f
substitut
ribos
ring
incorpor
differ
posit
sens
antisens
strand
result
sirna
test
variou
transfect
reagent
intranas
rsv
base
result
propos
follow
consensu
design
intranas
antivir
sirna
modifi
nt
long
doublestrand
sirna
function
lung
ii
excess
ome
f
modif
either
strand
sirna
reduc
efficaci
iii
limit
modif
sens
strand
benefici
although
precis
efficaci
may
positiondepend
firstgener
sirna
design
mimic
product
dicer
endonucleas
cleavag
long
duplex
termin
overhang
contain
natur
unmodifi
ribos
base
report
us
numer
laboratori
sirna
prove
effect
cell
cultur
anim
particular
mention
antivir
activ
sirna
see
chapter
first
document
us
respiratori
syncyti
viru
rsv
proofofconcept
studi
synthet
unmodifi
sirna
design
essenti
viral
gene
prevent
rsv
growth
cultur
lung
epitheli
cell
translat
success
anim
model
reason
logic
rout
deliveri
sirna
nose
intranas
first
noninvas
second
involv
rel
simpl
applic
procedur
nasal
drop
aerosol
inhal
third
sirna
drug
follow
rout
viru
reach
tissu
includ
lung
lastli
subsequ
result
show
intranas
administ
sirna
remain
lung
leach
blood
tissu
minim
risk
system
side
effect
data
shown
chapter
therefor
focus
intranas
deliveri
antirespiratori
viral
sirna
first
summar
progress
made
four
major
respiratori
virus
rsv
parainfluenza
viru
piv
influenza
viru
flu
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
first
three
virus
clinic
signific
claim
larg
number
human
live
year
throughout
world
annual
flu
epidem
alon
affect
us
popul
averag
hospit
partli
due
high
mutat
rate
rna
genom
definit
vaccin
reliabl
antivir
treatment
virus
ribavirin
ifn
although
sometim
use
rel
nonspecif
toxic
regard
molecular
featur
genom
rsv
piv
nonseg
negativestrand
rna
virus
belong
differ
genera
paramyxovirida
famili
flu
orthomyxoviru
contain
segment
negativestrand
rna
genom
coronovirus
sarscov
contain
positivestrand
envelop
rna
genom
common
among
rna
virus
encod
gene
rnadepend
polymeras
rdrp
transcrib
replic
genom
host
anim
cell
devoid
activ
mani
potent
antivir
sirna
therefor
target
viral
gene
code
rdrp
subunit
relat
rdrp
function
includ
eg
p
phosphoprotein
l
larg
see
tabl
n
nucleocapsid
gene
rsv
p
l
gene
piv
pa
n
gene
flu
replicas
gene
sarscov
case
sirna
design
essenti
viral
gene
optim
cell
cultur
use
intranas
appropri
anim
model
antivir
activ
shown
rsv
parainfluenza
viru
piv
use
balbc
mous
model
well
studi
sirna
deliv
complex
either
oligofectamin
invitrogen
carlsbad
ca
miru
transit
tko
reagent
see
sect
although
uncomplex
intranas
sirna
also
show
signific
efficaci
compar
untreat
mice
intranas
sirna
complex
oligofectamin
polyethyleneimin
pei
also
protect
highli
pathogen
influenza
virus
subtyp
mice
notwithstand
success
activ
sirna
transient
last
day
therefor
enhanc
intracellular
extracellular
stabil
synthet
sirna
increas
without
compromis
rnai
activ
continu
goal
therapeut
translat
rnai
varieti
chemic
modif
includ
termin
intern
one
ad
firstgener
sirna
sequenc
improv
stabil
deliveri
lead
call
secondgener
sirna
advantag
taken
two
target
sequenc
rsv
l
gene
mrna
long
strain
aan
tt
motif
n
region
underlin
shown
top
thermodynam
differ
stabil
two
termini
shown
parenthesi
tend
prefer
ccc
stretch
end
n
sequenc
despit
slightli
favor
valu
subsequ
sirna
base
sequenc
bold
modif
underlin
f
modif
confirm
antivir
efficaci
modifi
sequenc
cell
cultur
well
mice
data
shown
dtdt
part
add
stabil
sirna
free
oh
group
ribos
moieti
rna
contrast
dna
lack
oh
group
variou
substitu
ad
pursu
two
promis
one
name
omethyl
flourid
f
latter
modif
place
pyrimidin
nucleosid
c
u
lead
fc
fu
residu
number
previou
studi
substitut
introduc
variou
extent
antisens
strand
guid
strand
strand
sirna
shown
enhanc
stabil
potenc
although
intranas
applic
test
addit
tend
reduc
sirnadriven
innat
immun
respons
systemat
studi
cell
cultur
biochem
function
activ
sirna
vindic
found
affect
posit
modif
sequenc
gener
speak
modifi
ribonucleotid
end
antisens
strand
less
activ
rel
modifi
one
intern
f
gener
welltoler
antisens
strand
show
signific
shift
activ
depend
posit
contrast
incorpor
sens
strand
sirna
show
strong
posit
prefer
comprehens
studi
howev
intern
modif
either
strand
actual
made
sirna
less
activ
anim
experi
oh
residu
sirna
hepat
b
viru
substitut
f
administ
intraven
iv
lipid
complex
f
sirna
show
improv
efficaci
longer
halflif
plasma
liver
sirna
addit
reveal
accumul
liver
spleen
lung
explain
success
iv
administr
hepat
suggest
ineffect
rout
lung
infect
base
absenc
uniform
pattern
studi
reason
substitut
secondgener
sirna
respiratori
virus
individu
optim
follow
step
design
firstgener
sirna
follow
gener
accept
sequenc
rule
ii
select
one
lowest
ic
prefer
nm
cell
cultur
assay
viru
growth
iii
add
ome
f
substitut
variou
format
ie
number
placement
iv
ensur
substitut
either
improv
reduc
knockdown
effici
screen
cell
cultur
v
confirm
efficaci
lack
toxic
anim
model
vi
test
improv
stabil
serum
blood
vitro
final
deem
necessari
resourc
permit
lowor
highthroughput
assay
offtarget
effect
perform
ensur
target
specif
present
consensu
procedur
test
laboratori
follow
step
essenti
protocol
use
test
modif
long
synthet
chemistri
avail
reagent
describ
use
success
us
variou
equival
avail
commerci
optim
synthet
sirna
chosen
sequenc
lyophil
purchas
without
modif
nmol
dharmacon
lafayett
co
assum
reader
access
appropri
cell
cultur
facil
consist
incub
cultur
hood
avail
expertis
viru
growth
assay
chapter
cover
specif
issu
relat
test
antivir
sirna
rsv
rnasefre
gelload
microcapillari
tip
vwr
use
free
onlin
sirna
design
program
target
mrna
sequenc
see
note
gener
use
one
avail
whitehead
institut
mit
server
follow
url
http
jurawimitedubiocsirnaext
registr
requir
free
copi
past
target
sequenc
box
initi
choos
aan
tt
recommend
pattern
usual
need
chang
filter
criteria
ie
leav
default
click
search
button
rsv
l
gene
found
mani
prospect
one
lead
tabl
prospect
sirna
sequenc
order
accord
thermodynam
valu
default
set
goal
select
sequenc
high
neg
valu
ie
sequenc
closer
top
tabl
addit
visual
examin
central
n
part
ie
ignor
first
two
last
two
nucleotid
pick
one
atrich
end
right
hand
side
gcrich
end
left
hand
side
number
sequenc
one
test
realli
depend
avail
resourc
order
least
given
target
order
sens
strand
n
dtdt
antisens
strand
n
dtdt
n
part
complementari
n
sequenc
provid
exampl
test
function
sirna
sequenc
base
l
polymeras
gene
rsv
tabl
assum
receiv
sirna
roughli
week
order
purchas
smallest
amount
initi
save
money
gener
nmol
heat
mixtur
min
remov
heat
centrifug
briefli
allow
solut
cool
room
temperatur
min
allow
format
doublestrand
sirna
readi
use
sirna
concentr
stock
solut
see
note
aliquot
sirna
small
volum
store
best
result
freezethaw
tube
four
time
trypsin
cell
seed
cell
l
complet
growth
medium
per
well
plate
incub
h
achiev
confluenc
immedi
transfect
add
l
optimem
steril
eppendorf
tube
add
l
transittko
reagent
mix
thoroughli
vortex
incub
room
temperatur
min
prior
intranas
administr
sirna
mous
see
note
must
anesthet
use
standard
procedur
avail
laboratori
eg
administ
nembut
via
intraperiton
ip
inject
recommend
drug
dosag
mice
mgkg
see
note
gentli
lift
mous
tail
place
cage
lid
grip
loos
skin
neck
immobil
head
mous
extend
tail
draw
skin
tight
abdomen
grip
tail
littl
finger
hold
mous
headdown
posit
disinfect
inject
site
lower
right
left
quadrant
abdomen
use
hypoderm
needl
administ
anesthet
mous
readi
sirna
administr
voluntari
movement
observ
place
anesthet
mous
lab
towel
face
head
immobil
insert
microcapillari
tip
contain
sirnatransfect
reagent
complex
see
note
nostril
use
rang
nmol
sirna
per
mous
eg
nmol
instil
solut
slowli
min
period
allow
anim
breath
liquid
see
note
return
mous
cage
monitor
least
min
avoid
depress
cardiac
andor
respiratori
function
also
found
least
potent
first
second
gener
sirna
term
intranas
antirsv
activ
without
increas
immun
reaction
data
shown
preliminari
experi
also
lent
well
f
modif
intranas
antivir
activ
data
shown
recommend
exact
format
optim
sequenc
follow
publish
dsirna
design
guidelin
although
describ
laboratori
mous
model
intranas
dosag
deliveri
easili
scale
laboratori
anim
sirna
concentr
pharmaceut
industri
prefer
express
drug
concentr
wtvol
wtbodi
weight
eg
mgkg
research
howev
easier
use
express
sirna
concentr
molar
unit
eg
nm
sinc
allow
direct
comparison
potenc
differ
sirna
even
differ
base
composit
modif
henc
formula
weight
nake
sirna
without
transfect
reagent
without
chemic
modif
seem
potent
reagentcomplex
sirna
intranas
antivir
test
although
mechan
entri
unknown
sinc
nake
sirna
would
free
reagent
toxic
worth
test
modifi
secondgener
sirna
nake
applic
well
recommend
use
pei
appar
toxic
intranas
applic
avoid
use
excess
liquid
may
suffoc
anim
caus
death
rule
keep
total
instil
volum
balbc
mice
higher
volum
may
toler
larger
speci
protocol
describ
may
modifi
aerosol
sirna
use
enclosur
hous
anesthet
anim
handheld
nebul
common
type
use
inhal
asthmat
larger
amount
sirna
need
fraction
aerosol
actual
inhal
anim
use
routin
consid
optim
commerci
motor
nebul
check
local
pediatrician
exact
model
vendor
usag
modifi
system
remov
facial
mask
deliveri
end
insert
tube
directli
enclosur
snug
fit
mask
reduc
sirna
wast
